Search Results - "Saretsky, Todd L"

Psychometric evaluation of the respiratory syncytial virus infection, intensity and impact questionnaire (RSV-iiiQ) in adults by Williams, Valerie, DeMuro Romano, Carla, Finelli, Lyn, Qin, Shanshan, Saretsky, Todd L, Ma, Jia, Lewis, Sandy, Phillips, Matthew, Osborne, Richard H, Norquist, Josephine M

“…Despite a number of respiratory syncytial virus (RSV) vaccine candidates being tested in clinical trials, disease-specific, self-reported instruments assessing…”
Get full text

Assessing the patient experience of respiratory syncytial virus infection: development of a patient-reported outcome measure by Romano, Carla DeMuro, Finelli, Lyn, Lewis, Sandy, Williams, Valerie, Martin, Emily, Phillips, Matthew, Saretsky, Todd L, Norquist, Josephine

“…Respiratory syncytial virus (RSV) causes significant morbidity and mortality in older adults. Despite a number of RSV vaccine candidates in clinical trials,…”
Get full text

Measuring dengue illness intensity: Development and content validity of the dengue virus daily diary (DENV-DD) by Jones, Amy M., Saretsky, Todd L., Panter, Charlotte, Wells, Jane R., White, Frances, Smith, Verity, Kendal, Helen, Russell, Kevin, Ruggieri, Madelyn, Calhoun, Shawna R., Gater, Adam, O’Hagan, Justin, Anderson, Kathryn B., Paz-Soldan, Valerie A., Morrison, Amy C., Ware, Lisa, Klick, Michelle, Thomas, Stephen, Marks, Morgan A.

“…Background Dengue is the most prevalent arboviral infection causing an estimated 50–60 million cases of febrile illness globally per year, exacting…”
Get full text

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study by Motzer, Robert, Porta, Camillo, Alekseev, Boris, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, Cella, David

“…Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib…”
Get full text

Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review by Motzer, Robert J., Rane, Pratik P., Saretsky, Todd L., Pawar, Deepshikha, Martin Nguyen, Allison, Sundaram, Murali, Burgents, Joseph, Pandey, Rishabh, Rudell, Katja

“…There is heterogeneity in the choice of patient-reported outcome measures (PROMs) and methodological approaches across clinical trials evaluating…”
Get full text

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma by Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Symeonides, Stefan, Hajek, Jaroslav, Ferguson, Thomas, Chang, Yen-Hwa, Lee, Jae Lyun, Haas, Naomi, Sawrycki, Piotr, Sarwar, Naveed, Gross-Goupil, Marine, Thiery-Vuillemin, Antoine, Mahave, Mauricio, Kimura, Go, Perini, Rodolfo F, Saretsky, Todd L, Bhattacharya, Rituparna, Xu, Lei, Powles, Thomas

“…In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was…”
Get full text

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings by Joseph, Richard W., Liu, Frank Xiaoqing, Shillington, Alicia C., Macahilig, Cynthia P., Diede, Scott J., Dave, Vaidehi, Harshaw, Qing, Saretsky, Todd L., Pickard, Alan Simon

“…Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited…”
Get full text

Three Novel Patient-Reported Outcome Measures to Assess the Patient Experience With Daily and Weekly HIV Oral Antiretroviral Therapy by Bailey, Julie R, Fonseca, Eileen, Borsa, Alexander, Hawryluk, Emily, Gubernick, Steven I, Motte, Anna de la, Karantzoulis, Stella, Reaney, Matthew, Saretsky, Todd L

“…Patient-reported outcome measures (PROMs) can provide data on the barriers and facilitators of adherence to daily oral antiretroviral therapy (OART) regimens…”
Get full text

Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response by Johnson, Kristen M, Devine, Jacob M, Ho, Kai Fai, Howard, Kellee A, Saretsky, Todd L, Jamieson, Carol A

“…This study investigated the suitability of the Montgomery-Asberg Depression Rating Scale (MADRS), with a 24-hour recall period (MADRS-24hr), to assess the…”
Get full text

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma by Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S.R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John

“…KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or…”
Get full text

Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study by Powles, Thomas, Albiges, Laurence, Jalkanen, Katriina Johanna, De Velasco, Guillermo, Burotto, Mauricio, Ghatalia, Pooja, Suárez, Cristina, Lam, Elaine T., Iacovelli, Roberto, Gumus, Mahmut, Verzoni, Elena, Kollmannsberger, Christian K., Stadler, Walter Michael, Venugopal, Balaji, Shinde, Reshma, Saretsky, Todd L., He, Li, Vickery, Donna, Choueiri, Toni K., Rini, Brian I.

“…361 Background: In the randomized, open-label, phase 3 LITESPARK-005 (NCT04195750) study, belzutifan treatment showed superior PFS (primary endpoint; HR 0.75…”
Get full text

Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Saretsky, Todd L., Ghate, Sameer R., Li, Xin Tong, Schloss, Charles, Fizazi, Karim

“…129 Background: The double-blind, phase 3, randomized KEYNOTE-921 trial (NCT03834506) showed that pembro + docetaxel did not significantly improve rPFS or OS…”
Get full text

Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) by Mehra, Niven, Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., McDermott, Raymond S., Sala González, Nuria, Fong, Peter C.C., Greil, Richard, De Santis, Maria, Yanez, Patricio Eduardo, Huang, Yi-Hsiu, Begbie, Stephen, Rey, Felipe, Kramer, Gero, Suzuki, Hiroyoshi, Saretsky, Todd L., Ghate, Sameer R., Cui, Yi, Kim, Jeri, Yu, Evan Y.

“…131 Background: The phase 3, randomized KEYLYNK-010 trial (NCT03834519) of pembro + ola vs next-generation hormonal agent (NHA) abi or enza did not…”
Get full text

Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings by Joseph, Richard Wayne, Liu, Frank Xiaoqing, Shillington, Alicia C., Macahilig, Cynthia, Diede, Scott J., Dave, Vaidehi, Harshaw, Qing, Saretsky, Todd L, Pickard, Alan S

“…Abstract only e21004 Background: Pembrolizumab (PEMBRO) and combination ipilimumab + nivolumab (IPI+NIVO) are FDA-approved immunotherapies for advanced…”
Get full text